The Indian pharmaceutical sector is offering investors a chance to build a strong portfolio under the theme “Ayush Kart”, as stated by Siddharth Sedani, Managing Director at Anand Rathi. The Indian pharma sector has been growing rapidly, and this trend is expected to continue, making it an attractive investment opportunity.<\/p>\n
The “Ayush Kart” theme is believed to have huge potential for growth, driven by the increasing demand for Indian pharmaceutical products globally. India is already a significant player in the global pharma industry, and its reputation for producing high-quality, affordable medicines is expected to drive further growth.<\/p>\n
Investors looking to capitalize on this trend can consider investing in companies that are focused on the development and manufacturing of pharmaceutical products. These companies are likely to benefit from the growing demand for Indian pharma products, both domestically and internationally.<\/p>\n
According to Sedani, the “Ayush Kart” theme is a promising investment opportunity, and investors should consider including it in their portfolios. However, it is essential for investors to consult with their investment advisers before making any financial decisions. This will help them make informed decisions and ensure that their investments are aligned with their financial goals and risk tolerance.<\/p>\n
The growth of the Indian pharma sector is expected to be driven by various factors, including the increasing demand for generic medicines, the rising prevalence of chronic diseases, and the growing awareness of the importance of healthcare. Additionally, the Indian government’s initiatives to promote the pharma industry, such as the “Pharma Vision 2020” plan, are expected to provide a boost to the sector.<\/p>\n
In conclusion, the “Ayush Kart” theme offers investors a chance to build a strong portfolio by investing in the growing Indian pharma sector. With its huge potential for growth, driven by increasing demand and government initiatives, this theme is expected to attract significant investment in the coming years. However, investors should exercise caution and consult with their investment advisers before making any financial decisions.<\/p>\n","protected":false},"excerpt":{"rendered":"
The Indian pharmaceutical sector is offering investors a chance to build a strong portfolio under the theme “Ayush Kart”, as stated by Siddharth Sedani, Managing Director at Anand Rathi. The Indian pharma sector has been growing rapidly, and this trend is expected to continue, making it an attractive investment opportunity. The “Ayush Kart” theme is […]<\/p>\n","protected":false},"author":1,"featured_media":88036,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","fifu_image_url":"","fifu_image_alt":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[26],"tags":[],"class_list":["post-89766","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-divis-laboratories"],"jetpack_featured_media_url":"https:\/\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/divis-lab-logo.jpg","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":89809,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/16\/indian-pharma-q3-preview-strong-domestic-formulations-segment-to-offset-us-pricing-challenges-scanx-trade\/","url_meta":{"origin":89766,"position":0},"title":"Indian Pharma Q3 Preview: Strong Domestic Formulations Segment to Offset US Pricing Challenges – scanx.trade","author":"Team Small News","date":"January 16, 2026","format":false,"excerpt":"The Indian pharmaceutical industry is expected to experience a mixed bag in the third quarter of the year, with domestic formulations likely to counterbalance the pressure from pricing in the US market. The sector's growth is anticipated to be driven by a strong performance in the domestic market, which is\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89749,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/04\/aurobindo-pharma-pushes-back-deadline-to-purchase-26-stake-in-swarnaakshu-solar\/","url_meta":{"origin":89766,"position":1},"title":"Aurobindo Pharma Pushes Back Deadline to Purchase 26% Stake in Swarnaakshu Solar","author":"Team Small News","date":"January 4, 2026","format":false,"excerpt":"Aurobindo Pharma has extended the timeline to acquire a 26% stake in Swarnaakshu Solar, a solar power company. The acquisition is part of Aurobindo Pharma's strategy to diversify its business and invest in renewable energy. The company had initially planned to complete the acquisition by a certain deadline, but it\u2026","rel":"","context":"In "Aurobindo Pharma"","block_context":{"text":"Aurobindo Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/aurobindo-pharma\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89744,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/03\/indias-pharmaceutical-sector-faces-a-pivotal-year-of-transformation-adapting-to-change-and-embracing-a-shifting-worldwide-landscape-hindustan-times\/","url_meta":{"origin":89766,"position":2},"title":"India’s pharmaceutical sector faces a pivotal year of transformation: Adapting to change and embracing a shifting worldwide landscape | Hindustan Times","author":"Team Small News","date":"January 3, 2026","format":false,"excerpt":"The Indian pharmaceutical industry has faced significant challenges in recent years, but 2022 has been a defining year for the sector. The industry has had to navigate disruptions caused by the COVID-19 pandemic, regulatory changes, and global trade tensions. Despite these challenges, Indian pharma has shown resilience and adaptability, and\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89791,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/12\/aurobindo-pharma-acquires-khandelwal-labs-non-cancer-portfolio-for-%e2%82%b9325-crore\/","url_meta":{"origin":89766,"position":3},"title":"Aurobindo Pharma Acquires Khandelwal Labs’ Non-Cancer Portfolio for \u20b9325 Crore.","author":"Team Small News","date":"January 12, 2026","format":false,"excerpt":"Aurobindo Pharma, a leading Indian pharmaceutical company, has acquired the non-oncology business of Khandelwal Laboratories for \u20b9325 crore. The acquisition is a strategic move by Aurobindo Pharma to expand its product portfolio and strengthen its position in the domestic market. Khandelwal Laboratories is a Mumbai-based pharmaceutical company that operates in\u2026","rel":"","context":"In "Aurobindo Pharma"","block_context":{"text":"Aurobindo Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/aurobindo-pharma\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89806,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/15\/us-sales-of-revlimid-decline-offset-by-strong-domestic-market-growth\/","url_meta":{"origin":89766,"position":4},"title":"US Sales of Revlimid Decline, Offset by Strong Domestic Market Growth","author":"Team Small News","date":"January 15, 2026","format":false,"excerpt":"The Indian pharmaceutical industry is bracing for a challenging earnings season in Q3, with expectations of muted margins due to the loss of patent exclusivity for the blockbuster blood cancer drug Revlimid in the US. Revlimid, which has generated over $100 billion in global sales, has been a significant revenue\u2026","rel":"","context":"In "Cipla"","block_context":{"text":"Cipla","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/cipla\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":89821,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/19\/sun-pharma-sets-sights-on-10-billion-organon-takeover-to-bolster-us-presence\/","url_meta":{"origin":89766,"position":5},"title":"Sun Pharma Sets Sights on $10 Billion Organon Takeover to Bolster US Presence","author":"Team Small News","date":"January 19, 2026","format":false,"excerpt":"Sun Pharmaceutical Industries Ltd., India's largest drug manufacturer, is considering a monumental acquisition of Organon, a US-based company specializing in women's health and biosimilars. The potential deal, valued at $10 billion, is being led by the company's founder, Dilip Shanghvi. If successful, this acquisition would be a significant milestone for\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"_links":{"self":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89766","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/comments?post=89766"}],"version-history":[{"count":0,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89766\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media\/88036"}],"wp:attachment":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media?parent=89766"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/categories?post=89766"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/tags?post=89766"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}